Scholarlink

<p>Allogeneic stem cell transplantation (alloSCT) remains a potentially curative treatment for patients with hematologic malignancies. Nevertheless, relapse and graft failure continue to be major barriers to long-term success. In these high-risk situations, a second alloSCT may represent the only curative option, although outcomes are frequently compromised by high non-relapse mortality and disease progression. Despite improvements in conditioning regimens, donor availability, and supportive care strategies, clinical results remain suboptimal and underscore the importance of careful patient selection.In this study, we report the 15-year experience of our institution—a national reference center for alloSCT in Spain—in managing patients undergoing a second alloSCT. Our objective is to evaluate relevant clinical and transplant-related factors associated with survival outcomes. Ultimately, we aim to enhance the selection process and contribute to a more personalized approach to 2nd-alloSCT, helping clinicians make better-informed decisions about which patients are most likely to benefit from this high-risk but potentially life-saving procedure.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic factors of survival in second allogeneic hematopoietic transplantation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月24日

查看全文
  • Rodrigo Cantera Estefanía,
  • Raquel García Ruiz,
  • Sara Fernández-Luis,
  • Juan José Domínguez-García,
  • Tatiana Fernández Barge,
  • Jon Salmanton-García,
  • Irene Francés Alexandre,
  • Ana Tobalina García,
  • Ana Gea Peña,
  • Irene Gorostidi Álvarez,
  • María Oviedo Madrid,
  • Julia Bannatyne Undabeitia,
  • Leddy Patricia Vega Suárez,
  • María Terán Díaz,
  • Miriam Sánchez Escamilla,
  • Mercedes Colorado Araujo,
  • Mónica López Duarte,
  • Lucrecia Yáñez San Segundo,
  • Enrique M. Ocio,
  • Arancha Bermúdez Rodríguez

摘要

Allogeneic stem cell transplantation (alloSCT) remains a potentially curative treatment for patients with hematologic malignancies. Nevertheless, relapse and graft failure continue to be major barriers to long-term success. In these high-risk situations, a second alloSCT may represent the only curative option, although outcomes are frequently compromised by high non-relapse mortality and disease progression. Despite improvements in conditioning regimens, donor availability, and supportive care strategies, clinical results remain suboptimal and underscore the importance of careful patient selection.In this study, we report the 15-year experience of our institution—a national reference center for alloSCT in Spain—in managing patients undergoing a second alloSCT. Our objective is to evaluate relevant clinical and transplant-related factors associated with survival outcomes. Ultimately, we aim to enhance the selection process and contribute to a more personalized approach to 2nd-alloSCT, helping clinicians make better-informed decisions about which patients are most likely to benefit from this high-risk but potentially life-saving procedure.